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Transferrin saturation with intravenous irons: An in vitro study.
Background. Iron deficiency anemia in chronic kidney dis-
ease is commonly treated with one of three intravenous irons—
iron dextran, iron sucrose, or iron gluconate. Substantial phar-
macologic differences between drugs exist, but their ability to
saturate transferrin has not been compared. Drugs that may
lead to rapid transferrin saturation may lead to greater efficacy
but also increased toxicity if transferring-mediated uptake of
iron is the basis of this toxicity.
Methods. We studied the in vitro ability of the three intra-
venous irons to donate iron to transferrin. Transferrin satura-
tion was studied by direct visualization of the transferrin bands
by urea polyacrylamide gel electrophoresis (PAGE), as well as
a functional assay that evaluated the ability of iron to half satu-
rate transferrin in a dose-dependent (0 to 100 lg/mL) and time-
dependent (15 to 180 min) manner. Half-maximal dose (EC50)
of iron needed to saturate transferrin was evaluated.
Results. Nondextran irons were able to saturate transferrin
in a dose-dependent and time-dependent manner. There was
more rapid transferrin saturation with iron gluconate compared
to iron sucrose. The slope of the EC50 versus dose iron glu-
conate titration curve was −0.021 nmol/lg/mL (95% CI −0.025
to −0.017, P < 0.0001), for iron sucrose −0.006 nmol/lg/mL
(95% CI −0.010 to −0.002, P = 0.002), and for iron dextran
−0.001 nmol/lg/mL (95% CI −0.004 to 0.003, P > 0.2). The
least square mean EC50 computed for mean iron concentra-
tion was 5.95 nmol for iron gluconate (95% CI 5.82 to 6.08),
6.73 nmol for iron sucrose (95% CI 6.59 to 6.86), and 7.24 nmol
for iron dextran (95% CI 7.11 to 7.38). Similar results were seen
for the time-dependent transferrin saturation (drug × time in-
teraction, F 6.0, P < 0.01). Urea PAGE analysis showed similar
results as the functional assay.
Conclusion. Substantial heterogeneity in direct iron trans-
fer from iron pharmaceuticals in vitro suggests that differences
may exist in safety and efficacy of these drugs in vivo. In vivo
studies are needed to compare the safety and efficacy of exist-
ing nondextran parenteral irons to better define the therapeutic
ratio.
Chronic kidney disease (CKD) is growing in public
health burden [1]. Anemia sets in early during the course
of CKD either as a result of erythropoietin deficiency,
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iron deficiency, or a combination of both [2]. Further-
more, a functional deficiency of iron may occur due to
enhanced erythropoiesis after therapy with recombinant
human erythropoietin (rHuEpo). Due to decreased iron
absorption in people with CKD, therapy with intravenous
iron (IVIR) is often necessary to improve anemia [3]. The
generation of oxidative stress, cell injury, and association
with cardiovascular disease has spawned research in the
potential mechanisms of injury [4, 5].
There are three preparations of IVIR available in
the United States—sodium ferric gluconate complex
in sucrose (Ferrlecit; Watson Pharma, Corona, CA,
USA), iron saccharate (Venofer; American Reagent
Inc., Shirley, NY, USA), and iron dextran with varying
pharmacology and toxicology profiles [6]. Whereas the
three drugs have been compared with respect to toxicity
in cell culture studies [7] and in vitro studies [8], the mech-
anism by which this injury occurs is not clear. One poten-
tial mechanism of toxicity could be different abilities of
these drugs to donate iron to transferrin. If rapid direct
transfer of iron to transferrin is the mechanism of injury,
a drug that would have the most rapid transfer would
be most injurious. This rapid transferrin saturation may
also influence the delivery of iron from the parent drug
to transferrin for subsequent delivery to tissues requiring
iron.
We reasoned that differences may exist in the direct
movement of iron from the existing parenteral irons to
transferrin. Accordingly, we studied the direct movement
of iron from the parent drug to transferrin molecule in
vitro with each of the three IVIR preparations using a
functional assay, as well as with direct measurement of
transferrin saturation.
METHODS
Functional assay of iron transfer by in vitro
apotransferrin titrations
Reagent preparation. All chemicals were purchased
from Sigma (Sigma Chemical Co., St. Louis, MO, USA),
with the exception of Chelex resin, which was purchased
from Bio-Rad (Hercules, CA, USA). Transferrin, when
saturated with Fe3+, has a maximal molar absorbtivity
at 470 nm that makes the quantification of iron binding
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capacity by spectrophotometric titration possible [9]. To
saturate iron-free human apotransferrin, 2 mmol/L ferric
nitriloacetic acid (Fe3+NTA) was prepared by combining
freshly prepared 6 mmol/L ferric nitrate with 2 volumes
of 12 mmol/L NTA, and then adjusting the pH to 7.4
with sodium bicarbonate powder using magnetic stirring
[10]. This Fe3+NTA solution was diluted with double dis-
tilled water to create 11 concentrations between 0 and
500 lmol/L for use in titrations. An 8 mg/mL solution of
human transferrin was prepared in 5 mmol/L Tris pH 7.4,
then 0.1 mol/L sodium bicarbonate was added to give
a final transferrin concentration of 7.2 mg/mL. Double
distilled water was treated with 300 mg Chelex resin per
10 mL overnight to remove excess iron, and the water
stored above the resin at 4◦C. Iron gluconate (Ferrlecit),
iron sucrose (Venofer), and iron dextran (Dexferrum)
were diluted with Chelex treated water to 200 lg iron/mL.
For dose-response studies, this solution was further di-
luted with treated water to give 200, 133, 100, 40, and
20 lg iron/mL.
Dose response studies. Aliquots (100 lL) of each of six
drug concentrations for each of three drugs were pipetted
to microplate wells, and 100 lL of 7.2 mg/mL transferrin
or bovine serum albumin (BSA) for samples and blank,
respectively, was subsequently added. Thus, each well had
an apotransferrin concentration of 3.6 mg/mL, reflecting
approximately the transferrin concentration that may ex-
ist in a person with iron deficiency anemia. The plates
were sealed with cover tape and incubated for one hour
at 37◦C. Following incubation, specimens were titrated
with 150 lL of Fe3+NTA to give an 11-point titration
curve. The absorbance at 470 nm was measured using a
microplate reader (Spectramax 190; Molecular Devices,
Sunnyvale, CA, USA). Each titration assay for each dose
of the drug was performed in triplicate.
Time course studies. Aliquots (100 lL) of 200 lg
iron/mL iron gluconate or iron sucrose were pipetted to
microplate wells, and 100 lL of 7.2 mg/mL transferrin
or BSA for samples and blank, respectively, was sub-
sequently added. This was repeated to give five identi-
cal microplates, each containing specimens in triplicate.
The plates were sealed with cover tape and incubated at
37◦C with a single plate removed at 15, 30, 60, 120, and
180 minutes. Immediately following removal from the in-
cubator, specimens were titrated with 150 lL of Fe3+NTA
to give an 11-point titration curve. The absorbance at
470 nm was measured using a microplate reader (Spec-
tramax 190, Molecular Devices).
Titration curve fitting
The amount of ferric iron (nmol) was plotted against
the absorbance at 470 nm. A sigmoid Emax model
with a baseline effect parameter (E0) was fitted using
WinNonlin 2.0 computer program (Pharsight Corp.,
Mountain View, CA, USA). The effect (E) that is the ab-
sorbance at 470 nm was modeled as E0+ (Emax − E0) ×
(Ac /(Ac + ECc50)). In this equation, A reflects the amount
of ferric iron, and c is the shape parameter. The amount
of iron needed to half saturate apotransferrin (EC50) was
calculated for each titration. A470 of BSA control was
subtracted from each specimen. Thus, a fall in EC50 in
the presence of drug would indicate partial saturation of
transferrin. No change in EC50 with increasing dose of
the drug would indicate no direct transfer of iron from
the drug to the transferrin molecule. Curve fitting was
carried out for each titration at each dose and time.
Direct visualization of transferrin saturation by
separation of molecular forms of transferrin
Iron-free apotransferrin can bind to two atoms of
iron to yield diferric transferrin. In addition, N-terminal
monoferric transferrin or C-terminal monoferric trans-
ferrin can be formed, the latter under acidic pH. The
iron forms of transferrin were separated using a Tris-
Borate-EDTA-Urea polyacrylamide gel (6% acrylamide
gels with 6 mol/L urea) according to a modified procedure
of Makey and Seal [11]. This method separates transfer-
rin into the apo form, the two monoferric forms, and the
diferric forms according to their electrophoretic mobili-
ties. To enable detection of the four transferrin bands in
plasma samples, all proteins except b− and c-globulins
were precipitated with 6,9-diamino-2-ethoxyacridine lac-
tate, commonly known as acridine. The electrophore-
sis apparatus used was from Bio-Rad Criterion system
(Bio-Rad). Proteins were stained with Commassie bril-
liant blue R-250 (Bio-Rad), and commassie stained gels
were scanned with Kodak Gel Logic 100 Imaging System
(Scientific Imaging Systems; Eastman Kodak Co., New
Haven, CT, USA). Densitometry was performed with
Kodak 1D Image Analysis Software (Scientific Imaging
Systems; Eastman Kodak Co.). The relative amount of
transferrin saturation was calculated as 1/2× (Monoferric
band(s) density) + 1 × (Diferric band density)/(Density
of apotransferrin + monoferric + diferric band).
Dose response and time course studies were performed
using the same concentration of apotransferrin and the
drugs as noted above.
Statistical analysis
Our major interest was to see a time-dependent
and dose-dependent change in iron transfer from three
drugs to apotransferrin molecule. A dose response (con-
centration of drug vs. EC50 of Fe3+NTA) and time-
dependent (time drug incubated vs. EC50 of Fe3+NTA)
response between the three drugs was constructed using
the titration methodology or by direct visualization of
electrophoretic bands by densitometry, as previously out-
lined. A separate-slopes model analysis of covariance
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Fig. 1. Dose response relationship of transferrin saturation with
increasing concentration of iron gluconate is shown (A). Numbers ad-
jacent to the curves are the concentrations of iron gluconate incubated
with human apotransferrin at 37◦C for one hour. Baseline absorbance
increases with incubation with the drug and the titration curve is shifted
to the left indicating that less ferric nitriloacetic acid (FeNTA) is needed
(ANCOVA) was used to test the significance of difference
between slopes of dose response and time-dependent
changes of iron transfer. In this model, both the type of
drug and drug × dose (or drug × time) parameters were
modeled against EC50. The F test for the drug × con-
centration (or drug × time) parameter was used to test
the significance of difference among slopes. Confidence
intervals (95%) were created for each slope, and if they
did not overlap, the significance between drugs was found
to exist at the 5% level. All analyses were conducted us-
ing Statistica for Windows 5.5 (Statsoft, Inc., Tulsa, OK,
USA).
RESULTS
There was no direct transfer of iron from iron dex-
tran to apotransferrin over three hours of incubation and
at all doses studied. In contrast, each of the nondextran
irons showed dose-dependent and time-dependent satu-
ration of transferrin. Figure 1 shows the dose-dependent
and time-dependent nature of the relationship. Dose re-
sponse relationship of transferrin saturation incubated
for one hour with increasing concentration of iron glu-
conate is demonstrated by the graph on the left (Fig. 1A).
With increasing concentration of iron gluconate incu-
bated (shown by numbers adjacent to the curves in
lg/mL) the baseline absorbance increased. In addition,
less ferric nitriloacetic acid (FeNTA) was needed to half
saturate apotransferrin (EC50). Titration curves of apo-
transferrin incubated with 100 lg/mL iron gluconate in
3.6 mg/mL human apotransferrin for 15, 60, 120, and
180 minutes are shown in Figure 1B. The EC50 falls with
increasing duration of incubation, reflecting the progres-
sive transfer of iron to transferrin.
Figure 2 shows the dose-response relationship or phar-
maceutical incubated and iron saturation of transferrin.
Varying concentrations of iron as gluconate, sucrose, or
dextran were incubated for one hour, and the half max-
imal saturation dose of FeNTA (EC50) plotted for each
pharmaceutical. Iron dextran showed no direct transfer
to transferrin. In contrast, iron sucrose and iron gluconate
had significant dose-dependent saturation of transferrin.
Iron gluconate had greater transfer of iron compared to
iron sucrose. The pharmaceutical × drug concentration
effect was highly significant (F 46, P < 0.0001). Thus,
the slopes of the lines were significantly different from
each other. The slope of the iron gluconate titration
curve was −0.021 nmol/lg/mL (95% CI −0.025 to −0.017,
to saturate apotransferrin with increasing time of incubation with the
drug. Titration curves of apotransferrin incubated with 100 lg/mL iron
gluconate in 3.6 mg/mL human apotransferrin for 15, 60, 120, and 180
minutes are shown (B). Curve-fitting equation is indicated (see text for
details).
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Fig. 2. Varying concentrations of iron as gluconate, sucrose, or dex-
tran were incubated for one hour and the half maximal saturation dose
of FeNTA (EC50) plotted for each pharmaceutical (A). Iron dextran
showed no direct transfer to transferrin. In contrast, iron sucrose and
iron gluconate had significant dose-dependent saturation of transferrin.
Iron gluconate had greater transfer of iron compared to iron sucrose. A
solution containing 100 lg/mL iron gluconate or iron sucrose was incu-
bated in human apotransferrin for varying time intervals, as denoted on
the x-axis (B). Control specimen contained iron-free water. Compared
to controls, both iron sucrose and iron gluconate caused transferrin
saturation (F = 6.0, P < 0.01 for drug × time interaction effect).
P < 0.0001), for iron sucrose −0.006 nmol/lg/mL (95%
CI −0.010 to −0.002, P = 0.002), and for iron dextran
−0.001 nmol/lg/mL (95% CI −0.004 to 0.003, P > 0.2).
Because there was no overlap between the CIs, each iron
is unique in its ability to transfer iron to transferrin. The
least square mean EC50 computed for mean iron concen-
tration was 5.95 nmol for iron gluconate (95% CI 5.82 to
6.08), 6.73 nmol for iron sucrose (95% CI 6.59 to 6.86),
and 7.24 nmol for iron dextran (95% CI 7.11 to 7.38).
Similar results were seen for the time-dependent trans-
ferrin saturation (drug× time interaction, F 6.0, P <0.01).
The slope of the drug-free control was no different from
0. However, compared to controls containing iron-free
water without drug, both iron sucrose and iron gluconate
caused greater transferrin saturation in a time-dependent
manner. The least square mean EC50 computed for mean
iron concentration was 5.40 nmol for control (95% CI 4.95
to 5.85), 5.09 nmol for iron sucrose (95% CI 4.83 to 5.35),
and 3.69 nmol for iron gluconate (95% CI 3.42 to 3.96).
The data of the functional assays as reported above
were confirmed by direct visualization of the molecular
forms of transferrin using urea polyacrylamide gel elec-
trophoresis (PAGE). Figure 3 shows urea-PAGE of trans-
ferrin incubated for varying times with 100 lg/mL of iron
gluconate (left) or iron sucrose (right). Control lane has
apotransferrin alone showing a single band. After varying
times of incubation (shown on top of each lane), there is
greater proportion of saturation seen with iron gluconate
compared to iron sucrose. To quantify the results of the
PAGE we performed densitometric analyses, which are
reported in Figure 4. Dose response and time-dependent
transfer of iron from each pharmaceutical to transferrin
based on urea-PAGE analysis is clear. No direct transfer
occurred with iron dextran, but nondextran irons showed
direct transferrin saturation. Greater tendency for satu-
rating transferrin is seen with iron gluconate compared
to iron sucrose.
DISCUSSION
Our study demonstrates that there is a direct transfer
of iron from nondextran irons to transferrin in vitro us-
ing a functional assay (titration of transferrin with iron),
and by direct visualization of transferrin saturation (urea-
PAGE). The direct transfer of iron from nondextran iron
occurs in a dose-dependent and time-dependent manner.
Finally, the rate of transfer of iron is greatest with iron
gluconate compared to iron sucrose. Our results com-
plement those of Esposito et al [12], who found greater
accessibility to iron with iron gluconate compared to iron
sucrose using fluorescent desferrioxamine.
Clinical implications of findings relate to the risk-
benefit ratio of intravenous irons in the treatment of ane-
mia. For effective erythropoiesis to occur, iron needs to
be delivered to the erythron via transferrin through up-
take by transferrin receptors. The ease of transfer from
iron gluconate to transferrin implies that this may have
greater efficacy compared to the others. However, it is
possible that increased delivery to the cells may also lead
to cytotoxicity. In elegant studies, von Bonsdorff et al [13]
have demonstrated that bleomycin-detectable iron that is
catalytically active is more often present when the trans-
ferrin saturation exceeds 80%. There are no comparative
data on the efficacy of intravenous irons. However, data
on comparative toxicity of these drugs are available in
vitro.
Zager et al [14] studied the effects of different iron
preparations (iron dextran, iron sucrose, iron gluconate,
and iron oligosaccharide) in mouse proximal tubular seg-
ments, cultured human proximal tubular cells, and bovine
aortic endothelial cells. Although each of the irons tested
increased oxidative stress, the pattern of cytotoxicity was
quite different. Thus, lethal cell injury as assessed by
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Fig. 3. Urea polyacrylamide gel elec-
trophoresis (PAGE) of transferrin incubated
for varying times with 100 lg/mL of iron
gluconate (left) or iron sucrose (right).
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Fig. 4. Dose response (A) and time-dependent (B) transfer of iron
from each pharmaceutical to transferrin based on urea-PAGE analysis
is shown. No direct transfer occurred with iron dextran but nondextran
irons showed direct transferrin saturation. Greater tendency for satu-
rating transferrin is seen with iron gluconate compared to iron sucrose.
lactate dehydrogenase (LDH) release in mouse and hu-
man tubular cells was seen only with iron sucrose, but
not with iron dextran or sodium ferric gluconate, on 1-
hour incubation. After incubation for 16 hours, lethal cell
injury was more common with iron sucrose. Cell viabil-
ity after 72 hours of iron exposure was least with iron
sucrose, intermediate with sodium ferric gluconate, and
most with iron dextran. The authors showed with a se-
ries of experiments that the generation of oxidative stress
with iron sucrose was dependent on mitochondrial respi-
ration, but not free iron—oxidative stress was not blocked
by the iron chelator desferoxamine. Furthermore, cyto-
toxicity was protected by reduced glutathione, not by its
antioxidant effect, but by providing cellular protection,
similar to glycine, in the setting of adenosine triphos-
phate (ATP) depletion. These experiments demonstrate
mitochondrial toxicity, cytotoxicity, and lipid peroxida-
tion with intravenous irons, and substantial heterogeneity
among iron preparations.
In the above experiments, the role of transferrin or
transferrin receptors in mediating iron toxicity was not
studied. Even if such data were available, it may be diffi-
cult to extrapolate the in vitro data to the in vivo scenario.
Direct transfer of iron to transferrin in vivo is likely to
be influenced by a number of factors. These factors may
include the half-life of the drug, distribution in the cen-
tral and peripheral compartments, circulating transfer-
rin concentration, percent transferrin saturation, and pH.
For example, Parkkinen et al [15] have found that upon
administration of usual doses of iron sucrose to dialysis
patients, low transferrin concentration is associated with
greater likelihood of generation of bleomycin-detectable
iron, a form of catalytically active iron. According to the
package inserts, the half-life of iron gluconate is 1 hour,
iron sucrose is 6 hours, and iron dextran (Dexferrum) is
58.9 hours. The molecular weight of iron sucrose is 34 to
60 kD, iron gluconate is 289 to 440 kD, and for iron dex-
tran (Dexferrum) is 265 kD. Thus, the in vivo effects of
these drugs may be quite different. For example, even if
the ability of iron sucrose to saturate transferrin is lower
compared to iron gluconate, the increased half-life may
allow persistent transferrin saturation and consequent
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delayed injury. These data also do not imply that iron
dextrans should be preferred over nondextran irons. The
allergic potential and the risk of death with iron dextrans
are well recognized. Thus, studies to compare the safety
and efficacy of the existing nondextran IVIRs are needed
to clarify the biological significance of the in vitro findings.
Recent data suggest that peroxide-mediated iron
signaling pathways may have broader implications in
oxidant-mediated cell injury in cardiovascular disease.
Tampo et al [16] have shown that oxidative stress leads
to activation of intracellular iron regulatory protein-1
(IRP-1), which leads to overexpression of transferrin re-
ceptors on the cell surface. Increased transferring-bound
iron leads to increased hydroxyl radical, alkoxyl radical,
and perferryl iron production, mitochondrial oxidative
damage, caspase activation, and apoptosis in bovine aor-
tic endothelial cells. Rooyakkers et al [17] have shown
direct evidence of endothelial dysfunction within 10 min-
utes of intravenous iron sucrose injection, and Drueke
et al [18] have shown association of atherosclerosis with
dose of intravenous iron and advanced oxidative protein
products.
CONCLUSION
Substantial heterogeneity in direct iron transfer from
iron pharmaceuticals in vitro suggests that differences
may exist in safety and efficacy of these drugs in vivo. Our
data call for in vivo studies to compare the safety and
efficacy of nondextran IVIRs to clarify the risk-benefit
profile.
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